Head-to-head · WeighScore
G-Plans vs Remedy Meds
The verdict
Remedy Meds takes it — 55.6/100 to 53.8/100, but only just.
Remedy Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth provider offering compounded semaglutide and tirzepatide programs. G-Plans is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | G-Plans | Remedy Meds |
|---|---|---|
| WeighScore | 53.8/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #463 | #437 |
| Semaglutide | Not disclosed | $299/mo (starting dose, compounded) |
| Tirzepatide | Not disclosed | $399/mo (starting dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #463 · C
Strengths
- Both semaglutide and tirzepatide available
Where it loses points
- Pricing not publicly disclosed
Graded #437 · C
Strengths
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
Where it loses points
- Limited public information on program details
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.